1. Home
  2. TSAT vs LUNG Comparison

TSAT vs LUNG Comparison

Compare TSAT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telesat Corporation

TSAT

Telesat Corporation

N/A

Current Price

$51.67

Market Cap

697.5M

Sector

Industrials

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.98

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSAT
LUNG
Founded
1969
1995
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
697.5M
97.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
TSAT
LUNG
Price
$51.67
$1.98
Analyst Decision
Hold
Buy
Analyst Count
1
7
Target Price
$37.00
$5.38
AVG Volume (30 Days)
132.5K
330.8K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$23.01
$1.13
52 Week High
$61.54
$2.89

Technical Indicators

Market Signals
Indicator
TSAT
LUNG
Relative Strength Index (RSI) 56.20 46.42
Support Level $48.11 $1.20
Resistance Level $51.89 $2.16
Average True Range (ATR) 2.34 0.13
MACD 0.51 -0.06
Stochastic Oscillator 82.54 25.12

Price Performance

Historical Comparison
TSAT
LUNG

About TSAT Telesat Corporation

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: